Adagene Inc
ADAG
View Detailed Chart
2.050USD
-0.020-0.97%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
120.77MMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.97%
5 Days
-8.48%
1 Month
+4.59%
6 Months
+12.64%
Year to Date
+3.02%
1 Year
-8.89%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
9.643
Target Price
+365.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Growing
The company is in a growing phase, with the latest annual income totaling USD 103.20K.
Undervalued
The company’s latest PE is -3.98, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.95M shares, decreasing 13.86% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.90.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Ticker SymbolADAG
CompanyAdagene Inc
CEODr. Peter (Peizhi) Luo, Ph.D.
Websitehttps://www.adagene.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
